Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07107841 · ClinicalTrials.gov registry record · NA
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
A NA study of Alopecia and Androgenic Alopecia, sponsored by Acorn Biolabs.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07107841: Recruiting NA study of Alopecia and Androgenic Alopecia, sponsored by Acorn Biolabs.
NCT07107841 is a NA study of Alopecia and Androgenic Alopecia that is actively recruiting participants, run by Acorn Biolabs. The registered enrollment target is 60 participants, below the 120-participant average among 13 other Alopecia trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07107841, a NA study of Alopecia and Androgenic Alopecia, is actively recruiting participants, sponsored by Acorn Biolabs.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.
Primary Outcome
Non-vellus TAHC is the number of non-vellus (terminal) hairs within 1 cm² scalp
Conditions Studied
Interventions
- OTHER Autologous Hair Follicle-Derived Secretome
- OTHER Placebo Control
Study Locations (1)
California
- Ziering Medical - West Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2027-09-15 |
| Phase | NA |
What NCT07107841 shows while recruiting
NCT07107841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 120-participant average among 13 other Alopecia trials with a reported enrollment target (50% lower).
The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 2 interventions - of which Autologous Hair Follicle-Derived Secretome is the first listed.
NCT07107841 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07107841 about?
NCT07107841 is a clinical study titled "Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)". (SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quant...
What is the current status of trial NCT07107841?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-10-16. Estimated completion is 2027-09-15.
What conditions does trial NCT07107841 study?
This clinical trial studies the following conditions: Alopecia, Androgenic Alopecia, Baldness.
What interventions are being tested in trial NCT07107841?
The interventions under investigation include: Autologous Hair Follicle-Derived Secretome (OTHER), Placebo Control (OTHER).
Who is sponsoring clinical trial NCT07107841?
This trial is sponsored by Acorn Biolabs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07107841 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07107841's enrollment target sits among peer trials
60 6th of 13 higher than 8 of 13 other Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
-
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI